Under construction – not a live service
Sign in
Taking people in United StatesPhase 2

A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Osteoarthritis Pain

Key facts

Who runs it
Eli Lilly and Company
Where
Austin, Bay City, Bellevue, Birmingham, Bradenton, Chicago, City of Saint Peters, Dayton, DeLand, Duncansville, Fargo, Hamden, Lady Lake, Maitland, Merritt Island, Miami, New Bedford, New Orleans, New Port Richey, Ocala, Palm Springs, Phoenix, Renton, Riverside, Rochester, San Diego, Springfield, Sunrise, The Villages, Tulsa, Waltham, Winter Park, and Woodstock, United StatesSee the 35 sitesAlso in 1 other country, 1 site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
25 Jun 2026
Expected to end
Apr 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LY4065967
  • Placebo
Record updated
4 November 2026

Who can take part

Age
40 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have presence of index knee pain for more than 12 weeks at screening
  • Have an x-ray supporting diagnosis of osteoarthritis according to the American College of Rheumatology with a Kellgren-Lawrence grade 2 to 4 radiographic classification of index knee
  • Have a body mass index ≤40 kilograms per meter squared (kg/m²) (inclusive)
  • Have stable glycemic control as indicated by a glycated hemoglobin (HbA1c) less than or equal to 10 at time of screening

Who cannot take part

  • Have had a surgical procedure or therapeutic injection in the affected knee within 3 months prior to screening
  • Have presence of surgical hardware or other foreign body in the index knee
  • Have ongoing complex regional pain syndrome or other concurrent medical condition that could interfere with the evaluation of pain in the index knee
  • Have had any joint replacement of the lower extremity, such as hip, knee or ankle, in the 6 months prior to screening
  • Have history or current clinically significant cardiac disease, including arrhythmia, aortic aneurysm, heart failure, current electrolyte abnormalities, or any other conditions that could predispose to arrhythmia in the judgement of the investigator
  • Are pregnant or breastfeeding
  • Have an abnormal blood pressure (BP) (systolic BP greater than 140 millimeters mercury (>140 mm Hg) and diastolic BP>90 mm Hg) at screening

Where in United States

Also in 1 other country, 1 site

  • FutureSearch Trials of NeurologyAustin, United StatesContact: John Hudson (principal investigator)Taking people
  • Great Lakes Research Group, Inc.Bay City, United StatesContact: Jeffrey Potts (principal investigator)Taking people
  • Northwest Clinical Research CenterBellevue, United StatesContact: Arifulla Khan, MD (principal investigator)Taking people
  • Central Research AssociatesBirmingham, United StatesContact: David DeAtkine (principal investigator)Taking people
  • Bradenton Research Center, Inc.Bradenton, United StatesContact: Eric Folkens (principal investigator)Taking people
  • Northwestern UniversityChicago, United StatesContact: Thomas Schnitzer (principal investigator)Taking people
  • StudyMetrix ResearchCity of Saint Peters, United StatesContact: Timothy Smith (principal investigator)Taking people
  • META Medical Research InstituteDayton, United StatesContact: Priyesh Mehta (principal investigator)Taking people
  • Accel Research Sites - DeLand Clinical Research UnitDeLand, United StatesContact: Bruce Rankin (principal investigator)Taking people
  • Altoona Center For Clinical ResearchDuncansville, United StatesContact: Alan Kivitz (principal investigator)Taking people
  • Lillestol ResearchFargo, United StatesContact: Michael Lillestol (principal investigator)Taking people
  • CMR of Greater New HavenHamden, United StatesContact: Joseph Soufer (principal investigator)Taking people
  • K2 MEDICAL Research THE VILLAGESLady Lake, United StatesContact: Craig Curtis (principal investigator)Taking people
  • K2 Medical Research ORLANDOMaitland, United StatesContact: Brandon Lenox (principal investigator)Taking people
  • Merritt Island Medical Research, LLCMerritt Island, United StatesContact: David Kirk (principal investigator)Taking people
  • New Horizon Research CenterMiami, United StatesContact: Lazaro Nunez (principal investigator)Taking people
  • Suncoast Research GroupMiami, United StatesContact: Mark Kutner (principal investigator)Taking people
  • Lucida Clinical TrialsNew Bedford, United StatesContact: David Shih (principal investigator)Taking people
  • Delricht ResearchNew Orleans, United StatesContact: Patrick Dennis (principal investigator)Taking people
  • Suncoast Clinical Research, Inc.New Port Richey, United StatesContact: Cathy Barnes (principal investigator)Taking people
  • Renstar Medical ResearchOcala, United StatesContact: David Oliver (principal investigator)Taking people
  • Desert Oasis Healthcare Medical GroupPalm Springs, United StatesContact: Michael Jardula (principal investigator)Taking people
  • Arizona Research CenterPhoenix, United StatesContact: Louise Taber MD (principal investigator)Taking people
  • Synexus Clinical Research US, Inc.Phoenix, United StatesContact: Shawn Searle (principal investigator)Taking people
  • Rainier Clinical Research CenterRenton, United StatesContact: Sheryl Marks (principal investigator)Taking people
  • Artemis Institute for Clinical ResearchRiverside, United StatesContact: Jack Vu (principal investigator)Taking people
  • Rochester Clinical Research, LLCRochester, United StatesContact: Patrick Connors (principal investigator)Taking people
  • Artemis Institute for Clinical ResearchSan Diego, United StatesContact: Stacey Layle (principal investigator)Taking people
  • Clinvest Research, LLCSpringfield, United StatesContact: Ralph Duda (principal investigator)Taking people
  • Precision Clinical ResearchSunrise, United StatesContact: Richard Linn (principal investigator)Taking people
  • Charter Research - Lady LakeThe Villages, United StatesContact: Stephen Miller (principal investigator)Taking people
  • DelRicht ResearchTulsa, United StatesContact: Melita Tate (principal investigator)Taking people
  • MedVadis Research CorporationWaltham, United StatesContact: David DiBenedetto (principal investigator)Taking people
  • Conquest ResearchWinter Park, United StatesContact: Anand Patel (principal investigator)Taking people
  • North Georgia Clinical ResearchWoodstock, United StatesContact: Bram Wieskopf (principal investigator)Taking people

About the trial

What the trial wants to find out

The main purpose of this study is to test the safety and efficacy of study drug for the treatment of knee pain due to osteoarthritis (OA). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.

The 2 groups in the trial

  • LY4065967Treatment being tested

    LY4065967 administered orally.

  • PlaceboPlacebo, for comparison

    Placebo administered orally.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Osteoarthritis
Record updated
4 November 2026